Macquarie Begins Coverage on Genomic Health, Myriad Genetics

Macquarie Capital analyst Dane Leone gave Genomic Health an "Outperform" rating and a $34 price target, and Myriad a "Neutral" rating with a $20 share price.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.